US EditionSCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
- Novo Nordisk presented results at the American College of Cardiology's Annual Scientific Session in Chicago, showing that its diabetes pill Rybelsus reduced the risk of cardiovascular-related death, heart attack, and stroke by 14% compared to a placebo after four years in patients with diabetes and established heart disease.
- The late-stage Rybelsus trial, designed to examine cardiovascular benefits, involved just over 9,600 patients aged 50 and older who received either Rybelsus or a placebo in addition to their standard treatment regimen.
- Rybelsus lowered the risk of non-fatal heart attacks by 26% and non-fatal strokes by 12% compared to placebo, although common side effects included gastrointestinal issues like nausea, diarrhea, and constipation, which rarely led to patients discontinuing the medication.
- According to Stephen Gough, Novo Nordisk's global chief medical officer, the company has applied in the U.S. And EU to expand Rybelsus's approval to include lowering the risk of serious cardiovascular complications, providing an oral medication option for patients who prefer it over injections.
- Novo Nordisk also presented data from the STRIDE trial at the American College of Cardiology's Annual Scientific Session and Expo, demonstrating that once-weekly injectable Ozempic 1 mg improved maximum walking distance by 13% compared to placebo in adults with type 2 diabetes and symptomatic PAD, leading to a label extension application to the FDA with a decision anticipated in 2025, potentially addressing the critical unmet need for the approximately 12 million people in the United States impacted by PAD, particularly the one in four who also have type 2 diabetes.
63 Articles
63 Articles
Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action
Type 2 diabetes mellitus (T2DM) and obesity are metabolic disorders characterized by excess cardiovascular risk. Glucagon-like peptide 1 (GLP1) receptor (GLP1R) agonists reduce body weight, glycaemia, blood pressure, postprandial lipaemia and inflammation — actions that could contribute to the reduction of cardiovascular events. Cardiovascular outcome trials (CVOTs) have demonstrated that GLP1R agonists reduce the rates of major adverse cardiova…
Oral semaglutide vastly reduces heart attacks, strokes in people with type 2 diabetes
A large clinical trial, co-led by researchers at the UNC School of Medicine, has shown that the popular weight-loss drug significantly reduces cardiovascular events in people with type 2 diabetes, pre-existing cardiovascular disease, and/or chronic kidney disease.
Rutland Herald
SCORE analysis of semaglutide 2.4 mg demonstrated reduction in cardiovascular events in a real-world setting
Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment1SCORE is a retrospective, observational analysis of 27,963 patients with obesity or overweight and established cardiovascular disease1
Coverage Details
Bias Distribution
- 62% of the sources are Center
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
